Evidence map›Paper›PMID 33042469›Full record

ArticleAmerican journal of translational research2020

Ceramide synthase 6 predicts poor prognosis and activates the AKT/mTOR/4EBP1 pathway in high-grade serous ovarian cancer.

Yinong Shi, Chen Zhou, Huan Lu, Xiaoxiao Cui, Jun Li, Shuheng Jiang, Hao Zhang, Rong Zhang

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Tumor-derived RAC1Science advances · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Ceramide synthase 2-CFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yinong ShiFengxian District Center Hospital Graduate Student Training Base, Jinzhou Medical University Shanghai 201499, China.
Chen ZhouDepartment of Obstetrics and Gynecology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University Changzhou 213000, Jiangsu, China.
Huan LuFengxian District Center Hospital Graduate Student Training Base, Jinzhou Medical University Shanghai 201499, China.
Xiaoxiao CuiFengxian District Center Hospital Graduate Student Training Base, Jinzhou Medical University Shanghai 201499, China.
Jun LiState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200240, China.
Shuheng JiangState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200240, China.
Hao ZhangDepartment of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University Shanghai 200011, China.
Rong ZhangFengxian District Center Hospital Graduate Student Training Base, Jinzhou Medical University Shanghai 201499, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AKT/mTOR/4EBP1 signaling pathwaycell cycleCerS6High-grade serous ovarian cancer

Identifiers

PMID33042469
PMCPMC7540095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.